Brief: Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD

Ligand Pharmaceuticals Incorporated

27/06/2024 13:42

June 27 (Reuters) - Ligand Pharmaceuticals Inc  LGND.O :
    * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF
OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR
MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS
    * LIGAND PHARMACEUTICALS INC: ENTITLED TO RECEIVE A LOW
SINGLE-DIGIT ROYALTY ON WORLDWIDE NET SALES OF OHTUVAYRE
    * LIGAND PARTNER VERONA PHARMA ANNOUNCES FDA APPROVAL OF
OHTUVAYRE™ (ENSIFENTRINE), FIRST INHALED NOVEL MECHANISM FOR
MAINTENANCE TREATMENT OF COPD IN MORE THAN 20 YEARS

Source text for Eikon:  ID:nBw68br8ta 
Further company coverage:  LGND.O 

 ((Reuters.Briefs@thomsonreuters.com;))